

RENAL CARE GROUP INC

Form 8-K

March 03, 2005

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **March 3, 2005**

**RENAL CARE GROUP, INC.**

---

(Exact Name of Registrant as Specified in Charter)

**Delaware**

**0-27640**

**62-1622383**

(State or Other Jurisdiction  
of Incorporation)

(Commission File Number)

(I.R.S. Employer  
Identification No.)

**2525 West End Avenue  
Suite 600  
Nashville, TN 37203**

(Address of Principal Executive Offices, including Zip Code)

**(615) 345-5500**

(Registrant's telephone number, including area code)

**N/A**

---

(Former Name or Former Address, if Changed Since Last Report)

---

**TABLE OF CONTENTS**

Item 7.01. Regulation FD Disclosure.

Item 9.01. Financial Statements and Exhibits.

SIGNATURES

INDEX TO EXHIBITS

EX-99.1 SLIDE PRESENTATION

---

**Table of Contents**

Item 7.01. Regulation FD Disclosure.

Beginning on or about March 3, 2005 and continuing through no later than March 31, 2005, one or more officers of Registrant will make slide presentations to a number of shareholders of Registrant, as well as potential investors and investment analysts. The slide presentation contains, among other things, forward-looking information about Registrant and its business. The slides that the Registrant will use in these presentations are attached to this Current Report on Form 8-K as Exhibit 99.1.

Certain statements in the slide presentation constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based on currently available information. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Renal Care Group to differ materially from those expressed or implied by the forward-looking statements, including risks related to: our dependence on payments from private insurers for our profits; changes in the Medicare and Medicaid programs; reductions in reimbursement for the drug Epogen; increases in the price of Epogen or shortages of Epogen; changes in clinical practices; compliance with health care and other applicable laws; the integration of acquired businesses; competition; changes in the health care delivery, financing or reimbursement systems; and our substantial debt. These and other factors affecting Renal Care Group are discussed in more detail in Renal Care Group's reports filed with the Securities and Exchange Commission, including without limitation, Renal Care Group's annual report on Form 10-K for the year ended December 31, 2004.

The information in this current report on Form 8-K is furnished pursuant to Item 7.01 and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This current report on Form 8-K will not be deemed an admission as to the materiality of any information in the report that is required to be disclosed solely by Regulation FD. The Registrant undertakes no duty to update the information in this report and warns readers that the information included in this report will become stale after March 31, 2005.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits.

99.1 Slide presentation to be used at analyst and shareholder meetings between March 3, 2005 and March 31, 2005.

**Table of Contents**

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RENAL CARE GROUP, INC.

By: /s/ David M. Dill  
Name: David M. Dill  
Title: Chief Financial Officer

Date: March 2, 2005

- 3 -

---

**Table of Contents**

**INDEX TO EXHIBITS**

Exhibit Number	Description of Exhibits
99.1	Slide presentation to be used at analyst and shareholder meetings between March 3, 2005 and March 31, 2005